PXS 25 

PXS 25 is a cation-independent mannose 6-phosphate receptor (CI-M6PR) inhibitor that inhibits CI-M6PR-mediated activation of latent TGF-β₁. PXS 25 inhibits conversion of high glucose-induced latent TGF-β₁ to active TGF-β₁ in proximal tubule cells under normoxic conditions. PXS 25 suppresses high glucose-induced fibronectin, collagen IV production, and phosphorylated Smad 2 in proximal tubule cells under normoxic conditions. PXS 25 has antifibrotic properties in skin fibroblasts. PXS 25 can be used for the research of diabetic nephropathy^[1].

PXS 25 (1-200 µM; 72 h) inhibits high glucose-induced activation of latent TGF-β₁, downstream Smad2 signaling, and extracellular matrix production in normoxic HK-2 cells but does not affect hypoxia-related responses^[1].
PXS 25 (1-1000 µM; 72 h) shows no cytotoxic effect on HK-2 cells in normoxic or hypoxic conditions with 5 mM or 30 mM D-glucose (HY-B0389)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

362.31

C₁₅H₂₃O₈P

798546-78-8

O=P(O)(O)CC[C@H]([C@H]([C@@H]([C@@H]1O)O)O)O[C@@H]1OC2=C(C=C(C=C2)C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wong MG, et al. Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1. Am J Physiol Renal Physiol. 2011;301(1):F84-F93.  [Content Brief]